Abstract
Clinical trial evidence shows that biologic efficacy for severe asthma is related to biomarkers, but the extent to which this can be used to select treatments in the real-world is unclear.
Aims and objectives
We aimed to determine if pre-biologic measurements of biomarkers were predictive of lung function and asthma control in severe asthma patients treated with anti-IL5/5R or anti-IgE biologics in realworld settings.
Methods
The International Severe Asthma Registry collects data from 23 countries. We included all patients aged ≥18 years with data on blood eosinophil count (BEC), fractional exhaled nitric oxide (FeNO) or serum immunoglobulin-E (IgE) and with pre- and post-biologic FEV1 and asthma control.
Associations between outcomes one year after biologic initiation and highest pre-biologic biomarker levels were examined using regression models, adjusting for baseline measurement of the relevant outcome.
Results
Higher baseline BEC and FeNO were associated with greater post-treatment FEV1 improvement in anti-IgE and anti-IL5/5R patients, and reduced odds of uncontrolled asthma in anti-IL5/5R patients (Figure). IgE level was not associated with either of these outcomes. A combination of BEC and FeNO
predicted follow-up FEV1 improvement more accurately than either alone (pConclusions The results support the use of BEC and FeNO to help to identify patients who will benefit most from biologics.
Original language | English |
---|---|
Publication status | Published - 15 Jun 2023 |